FSHD is a rare, slowly progressive myopathy characterized by weakness initially in facial, shoulder, and upper limb muscles followed by abdominal and paraspinal weakness, and finally lower extremity weakness. FSHD affects between 16,000–38,000 people in the US, and its symptoms often progress over decades, creating significant challenges in tracking disease progression using in-clinic scales and functional tests.